<DOC>
	<DOCNO>NCT00749788</DOCNO>
	<brief_summary>The purpose study determine effect JTT-302 increase High Density Lipoprotein-Cholesterol ( HDL-C ) level administer daily four week subject low HDL-C level .</brief_summary>
	<brief_title>Efficacy Safety Study JTT-302 Subjects With Low HDL-C Levels</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Subjects Body Mass Index ( BMI ) ≤ 35 kg/m2 Subjects follow lipid parameter Visit 1 ( screen visit ) Visit 3 ( diet stabilization period ) : HDLC ≤ 40 mg/dL ( Men ) ≤ 50 mg/dL ( Women ) TG ≤ 500 mg/dL LDLC ≤ 190 mg/dL Subjects generally healthy determine prestudy medical history , physical examination , vital sign 12lead ECG Females pregnant breastfeeding AST , ALT total bilirubin ≥ 2.0 x ULN Visit 1 ( screen visit ) Visit 3 ( diet stabilization period ) Serum thyroid stimulate hormone ( TSH ) levothyroxine ( T4 ) outside central laboratory reference range screen visit Medical history diabetes mellitus two fast serum glucose measurement &gt; 126 mg/dL screen visit Subjects hypertension , two blood pressure measurement ≥ 140 mm Hg systolic ≥ 90 mm Hg diastolic screen visit History drug alcohol abuse within 12 month screen visit Use medication define protocol within sixweeks prior screen visit throughout study Use Cytochrome P450 3A4 inducer inhibitor , define protocol within four week screen visit throughout study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>